Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedNov 19, 2025
DataAggregated Company Financials
Companies1372
  • 7D-0.6%
  • 3M11.2%
  • 1Y4.8%
  • YTD8.5%

Over the last 7 days, the Healthcare industry has remained flat, although notably Eli Lilly gained 3.1%. The past year has been better, since the industry has gained 4.8% in that time. Earnings are forecast to grow by 17% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 20 Nov 2025US$6.2tUS$3.2tUS$133.4b25.1x46.8x2x
Sat, 18 Oct 2025US$6.0tUS$3.1tUS$140.4b24.8x42.4x1.9x
Mon, 15 Sep 2025US$5.7tUS$3.1tUS$137.6b22.7x41.6x1.9x
Wed, 13 Aug 2025US$5.4tUS$3.1tUS$140.0b23.4x38.5x1.7x
Fri, 11 Jul 2025US$5.6tUS$3.0tUS$127.9b24.4x43.5x1.8x
Sun, 08 Jun 2025US$5.5tUS$3.0tUS$127.2b24x43.2x1.8x
Tue, 06 May 2025US$5.6tUS$2.7tUS$126.0b24.7x44.2x2x
Thu, 03 Apr 2025US$5.5tUS$2.6tUS$81.7b26.5x67.9x2.1x
Sat, 01 Mar 2025US$5.8tUS$2.6tUS$79.3b27.5x73.2x2.2x
Mon, 27 Jan 2025US$6.0tUS$2.9tUS$85.5b27.9x70.7x2.1x
Wed, 25 Dec 2024US$5.8tUS$2.9tUS$78.3b27.4x74.5x2x
Fri, 22 Nov 2024US$6.0tUS$2.9tUS$77.0b27.9x77.6x2x
Sun, 20 Oct 2024US$6.2tUS$2.8tUS$58.8b32.2x106.2x2.2x
Tue, 17 Sep 2024US$6.3tUS$2.8tUS$60.2b30.6x105.1x2.2x
Thu, 15 Aug 2024US$6.1tUS$2.8tUS$55.7b30x109.1x2.2x
Sat, 13 Jul 2024US$6.3tUS$2.8tUS$62.2b31.2x101.1x2.2x
Mon, 10 Jun 2024US$6.2tUS$2.8tUS$63.6b30x97.5x2.2x
Wed, 08 May 2024US$6.1tUS$2.8tUS$64.8b32x94.3x2.2x
Fri, 05 Apr 2024US$6.2tUS$2.8tUS$83.9b32.1x73.6x2.2x
Sun, 03 Mar 2024US$6.3tUS$2.8tUS$85.0b31.2x74.1x2.3x
Tue, 30 Jan 2024US$6.3tUS$2.8tUS$90.7b32x69.8x2.2x
Thu, 28 Dec 2023US$6.2tUS$2.8tUS$91.5b33.1x68x2.2x
Sat, 25 Nov 2023US$5.9tUS$2.8tUS$91.4b28.6x64.4x2.1x
Mon, 23 Oct 2023US$5.7tUS$2.8tUS$99.6b25.6x57.7x2.1x
Wed, 20 Sep 2023US$6.0tUS$2.8tUS$98.6b28.3x60.9x2.2x
Fri, 18 Aug 2023US$6.1tUS$2.8tUS$99.3b28.2x61.9x2.2x
Sun, 16 Jul 2023US$6.0tUS$2.7tUS$110.9b26.3x54x2.2x
Tue, 13 Jun 2023US$6.0tUS$2.7tUS$110.0b25.8x54.4x2.2x
Thu, 11 May 2023US$6.0tUS$2.7tUS$111.8b24.9x54x2.2x
Sat, 08 Apr 2023US$5.9tUS$2.5tUS$121.9b24.2x48.6x2.4x
Mon, 06 Mar 2023US$5.8tUS$2.5tUS$122.5b25.3x47.3x2.3x
Wed, 01 Feb 2023US$6.0tUS$2.5tUS$133.9b23.8x44.5x2.4x
Fri, 30 Dec 2022US$6.0tUS$2.5tUS$135.9b23x44.4x2.5x
Sun, 27 Nov 2022US$6.0tUS$2.4tUS$133.6b24.1x45.1x2.5x
Price to Earnings Ratio

45.1x


Total Market Cap: US$6.0tTotal Earnings: US$133.6bTotal Revenue: US$2.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 46.8x which is lower than its 3-year average PE of 65.0x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have remained mostly flat over the last three years.
  • Meanwhile revenues for these companies have grown 9.2% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-3.08%
Healthcare-0.62%
Pharma1.92%
Biotech0.44%
Medical Equipment-1.73%
Life Sciences-1.84%
Healthcare Services-4.65%
Healthtech-8.16%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 61.4x.
    • Analysts are expecting annual earnings growth of 18.9%, which is higher than its past year's earnings decline of 5.1% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 24% over the next 5 years.
  • However this is lower than its past earnings growth rate of 52% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$1.05k3.1%
+US$28.5b		39.3%PE51x
JNJ Johnson & JohnsonUS$202.514.2%
+US$19.6b		32.3%PE19.4x
MRK MerckUS$95.053.9%
+US$8.9b		-2.5%PE12.4x
MDT MedtronicUS$100.344.7%
+US$5.8b		19.3%PE27.6x
GILD Gilead SciencesUS$128.073.8%
+US$5.8b		44.5%PE19.6x

Latest News

EXAS
US$86.18
Exact Sciences
7D
26.0%
1Y
63.5%

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too

Nov 20
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 37% But Its Business Prospects Need A Lift Too
ABT
US$126.15
Abbott Laboratories
7D
-2.1%
1Y
8.8%
GILD
US$128.07
Gilead Sciences
7D
3.8%
1Y
44.5%
AMGN
US$342.40
Amgen
7D
1.8%
1Y
18.9%
MDT
US$100.34
Medtronic
7D
4.7%
1Y
19.3%
MRK
US$95.05
Merck
7D
3.9%
1Y
-2.5%
VEEV
US$273.00
Veeva Systems
7D
-8.1%
1Y
29.6%
TMO
US$573.79
Thermo Fisher Scientific
7D
-2.4%
1Y
11.9%
UNH
US$309.09
UnitedHealth Group
7D
-8.8%
1Y
-48.5%
LLY
US$1,049.60
Eli Lilly
7D
3.1%
1Y
39.3%
JNJ
US$202.51
Johnson & Johnson
7D
4.2%
1Y
32.3%
CDTX
US$219.02
Cidara Therapeutics
7D
104.5%
1Y
1,348.5%
BMY
US$45.79
Bristol-Myers Squibb
7D
-6.7%
1Y
-20.9%
PFE
US$24.88
Pfizer
7D
-3.8%
1Y
-0.2%

PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts

Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.
CVS
US$76.55
CVS Health
7D
-4.6%
1Y
34.7%

CVS: Earnings Momentum Will Drive Performance as Regulatory Shifts Unfold

Analysts have raised their fair value estimate for CVS Health to $91.52 from $86.20. This adjustment is due to improved earnings visibility and continued momentum following solid quarterly results.
BSX
US$97.01
Boston Scientific
7D
-6.8%
1Y
7.6%

BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence

Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.